InsidersTradesSigma
삼성바이오로직스 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 삼성바이오로직스 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares trade on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 삼성바이오로직스 has published 2 reports. Market capitalisation: €70,686.3bn. The latest transaction was reported on 12 March 2026 (Other). Among the most active insiders: 컨두잇. The full history is free.
2
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 삼성바이오로직스 Strong Buy (bullish), based on 24 analysts. Average price target: ₩2,003,667.
Fundamental score
Ranked 9,161 of 28,064 companies
60.2
score / 100
Value36
Quality84
FCF yld1.1%
Earn yld2.5%
EV/EBITDA25.7x
ROE18%
Gross mgn55%
Net mgn39%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 March 2026
About 삼성바이오로직스
Samsung Biologics is a South Korean company specializing in the manufacturing of biopharmaceutical products. It is listed on the XKRX market.